foxo4 dri experience FOXO4-DRI - 10MG Development of a novel senolytic
Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv FOXO4 DRI FOXO4 p53 Interaction Blocker MedChemExpress FOXO4 DRI Beverly Hills Rejuvenation Center Tools to eliminate senescent cells Nature
Pay in 4 interest-free payments of $5.68 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4





